Skip to main content
ALGORAE PHARMACEUTICALS LIMITED logo

ALGORAE PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · 1AI ISIN · AU0000296022 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,159 across all filing types
Latest filing 2024-01-16 Board/Management Inform…
Country AU Australia
Listing ASX 1AI

About ALGORAE PHARMACEUTICALS LIMITED

https://algoraepharma.com/

Algorae Pharmaceuticals Limited is a biopharmaceutical company focused on the discovery and development of novel therapeutic solutions for complex medical conditions. The company leverages its proprietary artificial intelligence platform, AlgoraeOS, to streamline the drug discovery process and identify synergistic drug combinations. Its research pipeline primarily targets neurodegenerative diseases and other areas of high unmet clinical need. Key development programs include AI-116, a combination therapy aimed at treating dementia and Alzheimer's disease. By integrating advanced computational modeling with traditional pharmacological research, the company seeks to accelerate the transition of candidates from preclinical stages to clinical trials, optimizing therapeutic efficacy and safety profiles.

Recent filings

Filing Released Lang Actions
Change of Company Secretary 2 pages 215.9KB
Board/Management Information Classification · 100% confidence The document is a public announcement from Algorae Pharmaceuticals Limited regarding a change in the Company Secretary. It details the resignation of the previous Company Secretary and the appointment of a new one, including their qualifications and role. There is no financial data, no mention of financial results, reports, or regulatory filings beyond the ASX Listing Rule reference. The content is focused on management/board changes, specifically a key company officer change. Therefore, the document fits the category of Board/Management Information (MANG). The document length is about 5000 characters, which is consistent with a typical announcement of this nature.
2024-01-16 English
Notification of cessation of securities - 1AI 4 pages 23.9KB
Regulatory Filings Classification · 95% confidence The document is titled 'Notification of cessation of +securities' and details the expiry of options and convertible securities for Algorae Pharmaceuticals Limited. It includes specifics such as the number of securities ceased, reasons for cessation, and updated issued capital figures. The document is an announcement about changes in the company's securities, specifically the cessation of certain securities, rather than a financial report or detailed analysis. It is not a full financial report, earnings release, or management discussion. It fits the category of a regulatory announcement about securities status changes. Given the nature of the content, it aligns best with Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-01-04 English
Agreement with HL Pharma Addendum 2 pages 146.0KB
Regulatory Filings Classification · 95% confidence The document is a public announcement from Algorae Pharmaceuticals Limited regarding an updated supply agreement with HL Pharma for warehousing cannabinoid compounds. It provides details about the agreement, the companies involved, and the research programs. There is no financial data, no regulatory filing references, no voting results, no management changes, no earnings information, and no detailed financial or operational report. The document is an announcement of a business update related to supply chain and research collaboration. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Capital/Financing Update. It is a general corporate announcement about a business arrangement. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-01-04 English
Company name and stock code change 1 page 140.0KB
Regulatory Filings Classification · 95% confidence The document is a public announcement dated 8th September 2023 about a company name change from Living Cell Technologies Limited to Algorae Pharmaceuticals Limited and the corresponding ASX stock code change. It mentions shareholder approval of the name change with voting results. The document is short (3464 characters) and primarily serves as an announcement of a corporate action rather than a detailed report or financial statement. It does not contain financial data, management discussion, or regulatory filings beyond the announcement itself. The content fits best under a general regulatory announcement category rather than a detailed report or meeting material. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2023-09-07 English
Application for quotation of securities - LCT 6 pages 27.8KB
Share Issue/Capital Change Classification · 95% confidence The document is an application for quotation of securities on the ASX, detailing the issuance and conversion of options into ordinary shares. It includes specifics about the number of securities, issue dates, and classifications. This type of document is related to changes in the company's capital structure, specifically the issuance and quotation of new shares resulting from option exercises. It is not a financial report, earnings release, or management discussion, but rather an announcement about capital changes. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length and content confirm it is not a brief announcement but a detailed application for quotation, supporting a high confidence level.
2023-09-07 English
Cleansing Statement 1 page 98.3KB
Regulatory Filings Classification · 95% confidence The document is a Section 708A Cleansing Statement issued by Living Cell Technologies Limited, confirming the issuance of shares without disclosure under Part 6D.2 of the Corporations Act 2001. It includes compliance statements with relevant sections of the Corporations Act and is a formal notice related to share issuance and regulatory compliance. The document length is short (1493 characters) and it is a regulatory announcement rather than a full financial report or detailed filing. It does not contain financial statements or detailed financial data, nor is it a report or presentation. This type of document fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2023-09-07 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.